Clinical trials: Congestive Heart Failure Treated
Chronic Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction
Main objective: To evaluate the efficacy, safety and clinical dose exploration of Qishen Yiqi dripping pills in the treatment of chronic heart failure with preserved ejection fraction.
- Trial name
- NCT04944706
- Testing
- Qishen Yiqi dripping pills 4 bags/time
- Where
- 16 sites in China
- Volunteers
- 225 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Heart Failure
Feasibility Trial of the DC Devices Interatrial Septal Device (IASD) System
The purpose of this study is to evaluate the safety and potential benefits of the interatrial septal defect (IASD) System in patients with heart failure with preserved ejection fraction.
- Trial name
- NCT01570517
- Testing
- IASD System
- Where
- 3 sites in Australia, Czechia and 1 more
- Volunteers
- 11 people
- Sponsor
- Corvia Medical
Systolic Heart Failure
Spinal Cord Stimulation For Heart Failure
The primary objectives of this feasibility study are to determine the safety of spinal cord stimulation (SCS) as a therapy in patients with systolic heart failure and to gather observational information for potential efficacy…
- Trial name
- SCS HEART (NCT01362725)
- Testing
- Spinal cord stimulation system
- Where
- 5 sites in Australia, Hong Kong and 1 more
- Volunteers
- 20 people
- Sponsor
- Abbott Medical Devices
Iron-Deficiency Anemia, Iron-Deficiency
Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
Real-CHOICE - designed as a prospective, longitudinal, observational, non-interventional study - will investigate the attitude of patients and physicians towards IV (intravenous) iron therapy in general and IIM (iron isomaltoside…
- Trial name
- Real-CHOICE (NCT04318405)
- Testing
- Iron isomaltoside 1000
- Where
- 21 sites in Switzerland
- Volunteers
- 327 people
- Sponsor
- Pierre Fabre Pharma AG
Tricuspid Regurgitation, Tricuspid Valve Insufficiency
Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®
Retrospective prospective Multicentric clinical follow up of patients with severe tricuspid regurgitation after being treated with the TricValve® Transcatheter Bicaval Valves System.
- Conditions
- Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure
- Trial name
- NCT05114850
- Where
- 28 sites in Austria, Belgium and 3 more
- Volunteers
- 450 people
- Sponsor
- P+F Products + Features GmbH
Heart Failure, Congestive
The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure
The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure
- Trial name
- REMODEL (NCT00082589)
- Testing
- Eplerenone
- Where
- 53 sites in United States
- Volunteers
- 250 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Functional Mitral Regurgitation, Heart Failure
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).
- Conditions
- Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases
- Trial name
- NCT03142152
- Testing
- Carillon Mitral Contour System, Guideline Directed Heart Failure Medication
- Where
- 92 sites in United States, Canada and 6 more
- Volunteers
- 300 people
- Sponsor
- Cardiac Dimensions, Inc.
Heart Failure
C-Pulse® System: A Heart Assist Device Clinical Study
Sunshine Heart is sponsoring a prospective, multi-center, randomized trial to assess the safety and efficacy of the C-Pulse® System ("C-Pulse").
- Trial name
- COUNTER-HF (NCT01740596)
- Testing
- C-Pulse® System Counterpulsation
- Where
- 28 sites in United States
- Volunteers
- 38 people
- Sponsor
- Nuwellis, Inc.
Acute Heart Failure
Global Non-interventional Heart Failure Disease Registry
The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide.
- Trial name
- REPORT-HF (NCT02595814)
- Where
- 346 sites in United States, Algeria and 42 more
- Volunteers
- 18,805 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Atrial Fibrillation
Atrial Fibrillation Associated With Heart Failure Treated by BIOTRONIK's CRT-DX System
The purpose of the BIO-AffectDX Study is to prospectively evaluate improvement from baseline in heart failure subjects with atrial fibrillation (AF) implanted with a two-lead CRT-DX system, with emphasis on a comparison of…
- Conditions
- Heart Failure, Atrial Fibrillation, Cardiac Resynchronization Therapy
- Trial name
- BIO-AffectDX (NCT04870281)
- Testing
- CRT-DX
- Where
- 23 sites in United States
- Volunteers
- 13 people
- Sponsor
- Biotronik, Inc.
Heart Failure, Congestive
Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)
This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before…
- Trial name
- NCT00344513
- Testing
- Beta-blockers including Carvedilol, ACE inhibitors
- Volunteers
- 50,000 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Heart Failure, Reduced Ejection Fraction
Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice
This is an observational, non-interventional, longitudinal prospective descriptive study including participants diagnosed with Heart Failure with reduced Ejection Fraction (HFrEF) in Italy and initiated on treatment with…
- Trial name
- EVOLUTION-HF (NCT05250011)
- Testing
- Dapagliflozin
- Where
- 11 sites in Italy
- Volunteers
- 252 people
- Sponsor
- AstraZeneca
Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Secondary Use of PARALLEL-HF Data
This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group…
- Trial name
- NCT07527767
- Where
- Japan
- Volunteers
- 236 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Coronary Artery Disease
Cardiac REgistry of Celution Device for the Processing of Adipose-derived Regenerative Cells
This cardiac registry study will collect information from patients with ischemic or non-ischemic heart failure that have been treated with adipose-derived regenerative cells (ADRCs) delivered via intramyocardial injection.
- Trial name
- CREATE (NCT02735993)
- Sponsor
- Cytori Therapeutics
Hyperkalemia
Tracking Treatment Pathways in Adult Patients With Hyperkalemia.
This study aims to increase the understanding of Hyperkalemia (HK) management, treatment patterns, and the treatment decision-making process for the management of patients with HK over a period of up to 12 months.
- Trial name
- TRACK (NCT05408039)
- Where
- 74 sites in United States, Germany and 3 more
- Volunteers
- 1,331 people
- Sponsor
- AstraZeneca
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD).
- Trial name
- FIORELLO (NCT07192952)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 132 sites in United States, Argentina and 21 more
- Volunteers
- 117 people
- Sponsor
- Bayer
Cardiovascular Diseases, Heart Diseases
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Heart Failure
- Trial name
- INNOVATE (NCT06310031)
- Testing
- BrioVAD System, HeartMate 3
- Where
- 47 sites in United States
- Volunteers
- 780 people
- Sponsor
- BrioHealth Solutions, Inc.
Heart Failure, Congestive
TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients
Demonstrate the efficacy of the device-based managed therapy to treat atrial tachycardia and fibrillation (AT/AF) in patients with CHF indication for implant of a CRT defibrillator and to demonstrate the advantage of automatic…
- Trial name
- TRADE HF (NCT00345592)
- Testing
- Dual (atrial and ventricular) implantable defibrillator
- Where
- 2 sites in Italy
- Volunteers
- 420 people
- Sponsor
- Boston Scientific Corporation
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure
Tezosentan in the Treatment of Acute Heart Failure
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or…
- Conditions
- Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
- Trial name
- VERITAS 2 (NCT00524433)
- Testing
- tezosentan
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 713 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.